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ABSTRACT 
The primary aim of this project was to establish 
an in—house double antibody radioiimnunoassy for inhibin 
using reagent components obtained from the University 
of Monash, Australia, and to study the effect of 
^ ovarian stimulation on inhibin in women undergoing in 
vitro fertilization. 
An attempt was made to develop a double antibody 
inhibin RIA with supplied components. However, the 
assay was found to have no tracer binging activity. 
After some investigation, the possible cause of the 
problem was narrowed down to the binding activity of 
the first antibody of the assay. Since another batch 
of the antibody was not available, and there was 
, limited time allowed for this project; an alternative 
z inhibin EIjISA was used to do the inhibin analysis. 
The study showed that the inhibin level in the 
pre-ovulation phase was not affected by the up- or 
down:regulated state of the pituitary as effected by 
using short or long( G n R ^ agonist ovarian stimulation 
regimes. The inhibin^level just rose in response to 
the increase in FSH level. Also, the form of 
gonadotropin used (FSH did not affect the 
results in both groups. 
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The situation for the p<pst_ovulation phase was 
- ‘ ！ • 
different. The inhibin levels pontinued to increase in 
most of the patients studied after ovulation as the FSH 
levels fell. However, we are not sure whether the 
decrease in FSH level was due to an increase in inhifoin 




I. INHIBIN : A Brief Review 
1.1 Definition and Nomenclature, including related 
substances 
Inhibin is a 31kD glycoprotein hormone consisting 
of two dissimilar, disulphide—linked a and S subunits, 
which inhibits the production and/or secretion of 
___：^ pituitairy gonadotropins , preferentially that of FSH^. 
The sequence of the N-terminal amino acid was worked 
out independently by three independent groups working 
on follicular fluid (Miyamoto et al^ Robertson et al^ 
>0 and Liing et al^) in 1985• The a subunit is a 20kD 
protein which has been purified and cloned from porcine 
‘^ and human sources^ Two forms of the inhibin & subunit 
o 
have been isolated from follicular fluid and their gene 
sequences have been identified in man^ and rats? • The 
two S subunits of inhibin are referred to as S-A and S-
B. Two S subunits combine to form a molecule which 
stimulates FSH secretion, and is called activin; the 
homodimer of the S-A subunit is termed activin A and 
the heterodimer consisting of one S-A and one fi-B 
subunit is termed activin A-B. 
1 
1.2 Structure 
The a and S subunits of inhibin are linked by 
(bisulphide bonds (Figure 1^) . Two molecular weight 
’ forms of 58 kDa and 32 kDa were isolated; the 
subsequent cloning of the genes that independently code 
for the a and S subunits demonstrated that the 32 kDa 
form was a truncated product of the 58 kDa form due to 
cleavage of an N-terminal segment of the a subunit. 
Two forms of the E subunit have been isolated,- the Bj^  
subunit is one amino acid longer than the fig subunit and 
there is 70% homology between the deduced protein 
sequences for the S subunits. Inhibin dimers exist as 
inhibin A (a%) and inhibin B (aSg) . Both forms consist 
of identical a subunits and different S subunits. The 
飞 a subunit is initially synthesized as a preproprotein 
‘ and the S subunit as a proprotein^ • ？ 
? • 
The activins, originally isolated from porcine 
follicular fluid, are dimers of the S subunits of 
inhibin and exist as acitvin A (fi^ S^ ) and activin AB 
(S^Sg) • The SgSg dimer has not been isolated to date but 
has^ been produced in recombinant form. Activin A and 
activin AB stimulate FSH secretion by pituitary cells 
in vitro, thus opposing the action of the inhibins• 
Significant homology exists between the structures 
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species. The exon-intron structure of the genes coding 
！ 
for the human a subunits are also very similar between 
- species. The gene for the human a subunit also has a 
single 1.7 kb intron. Only one intron of approximately 
10 kb has also been demonstrated in the gene for both 
the human and bovine species. Full length of sequence 
of the human Eg gene was found to contain an intron of 
2.5 kb. 
The amino acid sequence of the a chain shows over 
85% homology between humans, pigs and cattle. 
Conservation of the S subunits between species is even 
higher, with the fi^ chain having only a single amino 
acid difference in the ovine sequence compared to those 
in pigs and humans^®. 
1.3 Historical Background of the Inhibin Concept 
The anterior lobe of the pituitary gland secretes 
gonadotropic hormones, i.e., luteinizing hormone (LH) 
and follicle—stimulating hormone (FSH)• The two 
gonadotropic hormones are synthesized and stored 
probably in the same pituitary cell type, although 
subtypes of pituitary gonadotrophs which only contain 
LH or FSH may also exitU. The biosynthesis and 
secretion of these glycoprotein hormones can be 
influenced by a number of stimulating factors. The 
4 
• hypothalamic gonadotropin-releasing hormone (GnRH) 
stimulates the release of both LH and FSH, whereas sex 
steroid hormones can suppress peripheral 
concentrations of gonadotropins by inhibiting the 
release of GnRH into the hypothalamic一hypophyseal 
portal circulation and by direct effects on the 
pituitary cells that produce the gonadotropins. 
The above mentioned factors affect the pituitary 
secretion of LH and FSH in a parallel fashion, i.e. if 
such factors stimulate the release of LH, they will 
also stimulate the release of FSH; and if they inhibit 
the release of LH, they will also inhibit the release 
of fsH^^. However, in a number of conditions, 
discrepancies have been observed between the changes of 
peripheral levels of LH and FSH. For example, in men 
with seminiferous tubule failure leading to male 
infertility, FSH levels may be elevated with 
testosterone and LH within the normal range; the sex 
steiroid oestradiol, inhibits both LH and FSH, has a 
biphasic effect, initial inhibition being followed by 
stiirmlation which affects LH more clearly than FSH. 
These discrepancies between the peripheral levels of LH 
and FSH have been explained in a number of ways^^. 
(1) The existence of a separate hypothalamic 
neurohormone for the secretion of FSH-releasing 
hormone (FSHRH), has been postulated. 
5 
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(2)y The differences between the metabolic clearance 
t 
rate of LH and FSH and also the difference in the 
response of the pituitary to GnRH to secrete the 
two gonadotropins. 
(3) The existence of the gonadal hormone inhibin which 
has been defined by its specific suppressive 
action on the pituitary secretion of FSH. 
In 1932, McCullagh suggested the existence of 
‘inhibin‘, an entity present in aqueous extracts of 
testes"• This entity, distinct from the substance 
•androtin丨(later characterized as testosterone) which 
was found in organic testicular extracts, was shown to 
prevent castration changes in the gonadotrophs of the 
pituitary of male rats that had been castrated. 
However, while the characterization of sex steroids and 
GnRH took place a number of years ago, the isolation of 
inhibin was only achieved in late 1985^^. Although 
c. 
” McCullagh and his coworkers performed a number of other 
experiments to prove the existence of inhibin, 
including experiments in which inhibin was injected 
into female rats to study the effects on the oestrous 
cycle of these animals, they did not succeed in proving 
their point without reasonable doubt. 
Meanwhile, the development of a bioassay for 
urinary LH and FSH, offered new possibilities for the 
6 
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investigation of tlie gonadal control of gonadotiropin 
secretion. Urinary丨FSH but not LH levels were found to 
be correlated with the degree of damage to 
spermatogenesis in infertile rats. The observation was 
. explained on basis of the "utilization theory" rather 
than on basis of the "inhibin theory". According to 
this utilization theory/ the selective increase of FSH 
levels was due to a lack of utilization of the hormone 
in the testes because of the absence df growing 
spermatogenic cells^^. 
Although testicular oestrogens might play a 
important role in the feedback action of the testis, 
experiments in which direct secretion of testicular 
oestrogens was estimated showed that the direct 
contribution of testicular oestradiol to the total 
amount of oestradiol produced in the male is small^^ 
Furthermore, exogenous oestradiol administrated in 
doses that result in "normal" peripheral concentrations 
of this steroid in castrated or intact animals, did not 
result in significant suppression of FSH levels. These 
observations make it highly unlikely that oestrogens 
play a important role in the specific feedback 
regulation of FSH secretion and indicate the possible 
importance of other hormones in this respect. 
The first indication for the existence of a FSH-
suppressing activity, which is secreted by the testes, 
7 
was provided by the experiments of Setchell and 
Jacks^^ who showed that administration of ovine rete 
testia fluid to castrated male selectively suppressed 
FSH level. 
More direct evidence for the presence of a 
substance (inhibin) which can cause specific inhibition 
of FSH secretion in ovarian follicle was provided by de 
Jong and Sharpel?, who showed that the immediate post-
castration rise of FSH, but not of LH, in adult male 
rats could be prevented by the injection of steroid-
free bovine follicular fluid. The first indication of 
actual secretion of a FSH-suppressing substance by the 
ovaries was obtained after transplantation of ovaries 
into the spleen of castrated male and female rats. FSH 
levels in these animal were selectively suppressed. 
More than 50 years elapsed between McCullagh's 
early proposal of the existence of inhilpin and its 
characterization. The causes of the delay appear to be 
due to: 
— ( 1 ) the difficulties encountered over the years 
in obtaining a reliable, reproducible and 
reasonably rapid assay for the measurement of 
FSH levels in biological fluids; 
(2) the problems caused by the absence of a 
quantitative, standardized, sensitive and 
8 
reliable assay for measuring inhibin 
activity, and 
(3) the apparent presence of numerous molecular 
weight forms of inhibin in gonadal extracts, 
‘ which cast doubt on the existence of inhibin 
as a believable entity, and rendered its 
ch:roinatographic treatment enormously complex. 
1.4 Actions of inhibin 
Inhibin and activin are produced by the granulosa 
cells of the follicle^^ or granulosa-lutein cells of 
the corpus luteum^^ In granulosa cell cultures, 
activin enhances the ability of FSH to induce 
aromatase activity by immature rat granulosa cells, an 
effect which was partially reversed by adding 
inhibin20， However, the role of inhibin in granulosa 
cells is not well characterised. 
In theca cells, inhibin enhances the LH—induced 
androgen production which is attenuated by activin* 
Recombinant human inhibin markedly enhanced the action 
of LH and insulin—like growth factor (IGF) in 
stimulating the production of androstenedione and 
dehydroepiandrosterone but not progesterone, in theca 
cells in c u l t u r e�� In the absence of LH or IGF, 
9 
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inhibin alone had veryJlittle action. However, activin 
suppressed the basal production of androgens in this 
system and inhibited the stimulatory effect of 
inhibin^. 
These findings suggest a mechanism by which the 
granulosa cells could influence theca cell function. 
FSH acts on the granulosa cell of the maturing follicle 
to inciuce aromatase activity, inhibin production, and 
LH receptors. The mature granulosa cells are able to 
produce large amounts of oestradiol provided there is 
an excess of androgen precursor. Inhibin produced by 
the granulosa cell enhances the action of LH on the 
theca cell, such that the supply of androgens is 
abundant. The granulosa cell progressively acquires LH 
receptors so that it becomes responsive to LH as well 
as FSH when it matures. In the follicular phase, LH 
stimulates the granulosa cells of the mature follicle 
to produce inhibin which further sensitizes the theca 
cells to the action of LH. Thus, within the follicle, 
a positive feedback loop is set up to ensure that 
maximum synthesis of oestrogen occurs in the late 
follicular phase when the amplitude of the LH pulse is 
rather low. 
1.5 Control of inhibin production 
There is strong evidence that FSH can stinmlate 
10 
inhibin production by the ovary^j 25, although the 
exact mechanism is not entirely understood. In vitro 
data has shown that FSH and testosterone enhance the 
induction of inhibin production by bovine26 and 
27 . immature human granulosa cells . 
1.6 Measurement 
1.6.1 Immunoassay 
The measurement of inhibin in biological fluids by 
immunoassays is complicated by the presence of the 
various forms of non-bioactive a subunits which may 
cross react with the antisera. Four types of 
immunoassays have been developed. 
^ The first type of assay is based on an antiserum 
^ raised to the synthetic amino terminal region of the 20 
kDa a subunit of inhibin^S and the results are 
expressed in terms of mass of synthetic peptide. These 
assays utilize iodinated amino terminal peptide as 
tracer. While activin, TGF—S, and Mullerian inhibitory 
substance cross react minimally, these peptide assays 
will detect a subunit as well as the whole inhibin 
molecule. Although robust, these assay are not 
sensitive or specific enough to measure inhibin in 
peripheral plasma of men and women. 
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The second type of assay is based on antiserum 
raised against native 58 kDa or 32 kDa whole inhibin 
molecule prepared from bovine follicular fluid^l 
iodinated whole bovine inhibin as tracer, and standards 
prepared from partially purified human follicular 
fluid. Under optimal conditions, the displacement 
caused by inhibin free serum is inodest (10 — 20%), 
although it is usual practice to supplement the 
standard with equal volume of serum from gonadectomized 
animals or postmenopausal women. These assays show 
little or no cross reactivity with a range of inhibin 
related proteins including activin, TGF-S, follistatin, 
and the a and S subunit after alkylation^^ 
The third type of assay is a two-site enzyme-
linked immunosorbent assay (ELISA) using two antibodies 
recognizing distinct epitopes on the a subunit. A goat 
polyclonal antibody is used as "capture" antibody and 
.coated on the wells of a microtiter plate. A mouse 
monoclonal antibody is conjugated to peroxidase and 
used as "tracer" antibody. No significant cross 
reactivity with TGF-S, LH, FSH, or activin was found by 
using this assay^^. 
The fourth type of immunoassay being developed is 
a two-site immunoradiometric assay (IRMA) using 
antibodies raised against synthetic peptide sequences 
corresponding to the N-terminus (1-32) of the a subunit 
12 
( and the N-terminus (84-112) region of the Zj^  subunit of 
\ 32 kDa human inhibin��. This assay has been used to 
measure inhibin in bovine follicular fluid, human 
follicular fluid, and an extract of rat ovary. 
However, it is not sensitive enough to measure inhibin 
in peripheral or even ovarian vein samples. It is also 
incapable of detecting some of the larger molecular 
weight forms of biologically active inhibin. 
1.6.2 Bioassay 
Inhibin activity can be detected by using a number 
of in vivo and in vitro bioassay systems. However, the 
main problem is the specificity of these systems^^ 
1.6.2.1 In vivo methods 
a) FSH suppression in rats 
Measurement of a fall in FSH levels following 
injection of test preparations in intact or 
castrated rats is a simple method for detecting 
inhibin activity, but is relatively insensitive 
— a n d quite imprecise• 
b) Prevention of post-castration rise of FSH 
Methods employing the administration of material 
immediately after castration to prevent the rise 
in FSH levels are probably more sensitive than the 
13 
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first method. However, jthese methods are 
imprecise, and paradoxical responses occur. 
c) Large animal models 
. Injection or infusion of inhibin preparations into 
sheep and monkeys will suppress FSH levels. 
Because of their size, large amounts of active 
materials are required, making this method not 
very practical. Moreover, protocols are labour 
intensive and special facilities are necessary for 
animal care and maintenance. 
d) Inhibition of FSH augmentation 
Inhibin preparations injected into immature female 
rodents will reduce the synergistic effect of 
endogenous FSH on the weight increase of the 
uterus or ovaries induced by hCG. These methods 
are very attractive because they are simple with 
very short turn-around time and radioimmunoassay 
is not required. H o w e v e r , they require animals of 
a specific age and may be less specific than other 
methods. 
1.6.2.2 In vitro methods 
a) Incubated hemipituitaries 
The GnRH-stimulated release of gonadotropins by 
14 
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pituitary halves is suppressed following the 
addition of inhibin preparations. Although it is 
- a simple and quick method, it is relatively 
insensitive and imprecise. 
b) Pituitary cell cultures 
Inhibin preparations suppress FSH secretion by rat 
pituitary cells in monolayer culture. Pituitary 
cell cultures have been used to develop a 
sensitive in vitro bioassay for inhibin. However, 
such set-ups may be sensitive to non-specific 
factors in the inhibin preparations e.g. ionic 
strength. 
These bioassays are not practical for 
physiological studies. Moreover, they do not have the 
precision and throughput capacity of immunoassays. 
However, bioassays are still essential for measuring 
the potencies of sources of inhibin and for monitoring 
their purification^^ 
1.7 Inhibin in clinical studies 
A lot of inhibin studies have been conducted since 
the confirmation of the existence of inhibin. For 
15 
I example, in the female, some work has been done to 
‘ investigate the role of inhibin in the normal human 
menstrual cycle. FSH levels were found to be regulated 
by inhibin during the luteal phase, and by E? in the 
follicular phase^^ The relationships of inhibin 
secretion to Eg, gonadotropin,, and progesterone^^ 
have been studied. Moreover, researches on clinical 
applications of inhibin determination have been 
started^^ Inhibin 丨 has been found to be a useful 
tumour marker in granulosa- cell tumours^® and mucinous 
carcinomas of the ovary”. 
Some work has been done on inhibin in IVF 
programs. For example, inhibin has been demonstrated 
to be a useful index of ovarian function in women with 
down- regulated pituitaries and ovarian stimulation 
prior to 工 Inhibin determinations can also be 
used to assess the follicle development and granulosa 
cell function in IVF^^. However, not much work has 
been done in this field. 
Patients undergoing ovarian hyperstimulation to 
prepare for IVF are good subjects for studying inhibin 
and FSH relationship in vitro. The administration of 
exogenous FSH in these patients supersedes their 
physiological control so that one can study how inhibin 
response to increased FSH levels without worrying about 
the inhibiting effect of inhibin on endogenous FSH 
16 
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release. In this project, we are interested in 
I • 
studying the effect on inhibin in ovarian 
hyperstimulation through administering exogenous 
gonadotropin(s), (FSH and/or hMG)； in two groups of IVF 
patients in whom pituitaries have been either up- or 
down- regulated by administration of GnRH agonist 
regime. 
i 
2• Project Protocol 
2.1 Background 
The use of gonadotropin-releasing hormone (GnRH) 
or its agonists prior to ovarian stimulation during an 
in vitro fertilization program has proven extremely 
valuable, giving increased pregnancy rates per embryo 
transfer, with a reduction in the number of cancelled 
cycles• 
The recruitment of primordial follicles, selection 
of a dominant follicle, and the progression to the 
preantral stage all appear to be influenced to a large 
extent by serum FSH concentration. In the normal 
ovulatory cycle, the dominant follicle produces a large 
amount of steroids ahead of other members of the cohort 
of recruited follicles to achieve follicle selection. 
Increasing oestrogen production by the dominant 
17 
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follicle(s) then exerts a negative feedback effect via 
the hypothalamopituitary axis and suppresses : FSH 
- release. This inhibits the ability of the remaining 
follicles to grow and they undergo atresia, while the 
maturing dominant follicle, having retained its LH and 
FSH receptors, is relatively protected from the 
declining serum FSH concentration and continues to 
42 develop to the preovulatory stage • 
The stimulation regimes being used are designed to 
provide increased circulating gonadotropins early in 
the follicular phase. This allows the recruitment of 
multiple follicles prior to endogenous selection of a 
dominant follicle. The increased gonadotropins 
supersede natural control mechanisms and provide the 
thrust for multifollicular development. Two regimes of 
GnRH agonist are being used (Figure . 
In the long (down-regulation) protocol, extended 
period of GnRH agonist administration down- regulates 
the pituitary. Whereas in the short (flare) protocol, 
GnRH agonist is given for a shorter period of time 
before HCG administration so that the pituitary is up-
regulated. In each protocol, gonadotropins are given 
either as FSH (75 lU per ampoule) or hMG (FSH + LH 75 
lU each per ampoule)• Please refer to appendices 1 and 
2 for the ward protocols. 
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2.2 Obj — t i v e s 
i 
This study was to compare the effect of down-
regulated pituitaries against up-regulated pituitaries 
on inhibin and other hormones in women undergoing in 
vitro fertilization, so that one knows more about the 
role of pituitary in the inhibin—gonadotropin control 
mechanism. Two groups of patients with long or short 
GnRH agonist administration were studied. 
The major part of this project was to develop an 
in-house inhibin radioimmunoassay using reagent 
components supplied by the University of Monash, 
Australia. In order to study the possible relationship 
between inhibin, gonadotropins, and sex steroids, the 
routine service of the Department of Chemical Pathology 
of Prince of Wales Hospital was used for measurement of 
gonadotiTopins and sex steroids using commercially 
available immunoassay kits. 
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II. MATERIALS AND METHODS 
i • 
1. Materials 
1 . 1 Tracer preparation and purification 
IODO-GEnR, (1,3,4,6-Tetrachloro-3a,6a-diphenyl 
glycoluril),was employed as the iodination reagent 
which resembles a 4-fold chloramine T molecule 
with a similar radiochemical yields^� 
(ImCi/lOiil) for the iodination was obtained 
from Amersham International PLC, Amersham 
Laboratories, England. 
Sephadex G25 and Matrex gel Red A used were 
products of Pharmacia, Sweden and Amicon, Danvers, 
USA respectively. All the other chemicals were 
purchased from E. Merck, Darmstadt, Germany 
1.2 Inhibin RIA 
The inhibin standard material used was a WHO 
research standard for inhibin, porcine (code no. 
86/690) with 2000 units per ampoule. 
The inhibin antiserum was supplied by the 
—�University of Monash, Australia, and was used in 
1:2,000 dilution in 0.IM P04/0.15M NaCl/0.1% 
sodium azide/0.5% BSA containing 1:600 normal 
rabbit serum. 
• � .. ' • 
Two precipitating second antibodies were tried. 
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The first one was a sheep anti rabbit 工gG antibody 
provided by Serotec, England. The second one was 
a goat anti rabbit precipitating antibody included 
in the growth hormone RIA kit from Diagnostic 
Products Corporation, USA. 
1.3 Other immnuoassays 
The INHIBIN-EASIA and progesterone kits were 
obtained from Medgenix D.iagnostics, Belgium and 
Diagnostic Products Corporation, USA respectively. 
The E2, LH and FSH kits were obtained from Abbott 
Laboratories, USA. 
2. In—house INHIBIN radioimmunoassay development 
This is a radioimmunoassay for inhibin in bovine 
and human follicular fluid (bFF'hFF) and serum from 
both species developed based on an antiserum raised in 
a rabbit to purified bovine 58 kDa inhibin. The RIA 
was modified for serum by using kDa inhibin as 
the tracer. 
2.1 The tracer preparation • 
(a) lodination 
lOug of lodogen dissolved in chloroform was added 
to a 2ml polystyrene tube and dried in a vacuum oven 
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before use. lOyL of a 0.5M phosphate buffer (pH 7.4) 
and 2]ig of inhibin protein for iodination (in 0 • 2M 
phosphate buffer, pH 7.4厂 were added to the tube 
containing the 工odogen. Nal25i imCi {10]il) was then 
added to the tube before mixing. The tube was incubated 
for 10 minutes at room temperature. 
(b) First Sephadex column purification 
The reaction was stopped by removing the reaction 
mixture from the tube. The iodination product was 
transferred to a 10ml glass column with Sephadex G25 
previously equilibrated with approximately 30ml 0.2M PO4 
0.1%BSA buffer pH6. 
5 drops fractions were collected per vial using 
， the 0.2M PO4/BSA buffer and the radioactivity was 
monitored by taking lOyl of the tracer for counting by 
a Gamma counter. The peak fraction(s) of 
radioactivity, between #8 _ 13, were pooled for Red A 
purification. 
(c) Matrex gel Red A column purification 
“ T h i s step was important because if it is excluded 
the percentage of tracer binding to the inhibin 
45 antiserum would be halved • 
Fraction 6, with the highest radioactivity, was 
diluted with 0.2M P04/0.1% BSA/0.1% Triton X-100 buffer 
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pH 6 to make up to a final yolume of 20nil. The diluted 
tracer was added to a Red A column (400iil of Matrex gel 
Red A in a plastic column washed with lOml 0. 2M PO4 0.1% 
BSA pH 6 before use)• The diluted tracer was allowed 
to run through the column and the wash (Wl) was 
collected. The wash (Wl) was applied to the column 
again and wash (W2) was collected. (Both Wl and W2 
were discarded later, after successful purification of 
• i 
tracer.) 
The Red A column was rinsed with 3ml of fresh 0.2M 
PO4/0.1%BSA/0.1% Triton X-100 buffer. The wash was 
discarded• The Red A column was finally eluted with 3 
X 1ml of 0.2 PO4/IM KC1/4M Urea/0.1%BSA. Therefore, 3 
X 1ml fractions of tracer were collected. 
(d) Second Sephadex column purification 
Each of the Iml fraction from the Red A column was 
applied to a separate Sephadex column (Sephadex G25 
10ml, equilibrated with 30inl of 0.2M P04/0.1% BSA/0.1% 
Triton X-100 buffer)• The columns were eluted with the 
PBS/BSA/Triton buffer and ten Iml fractions were 
collected from each column. The radioactivity in lOyl 
aliquot was determined. The fractions containing the 
peak radioactivities were pooled and used as the tracer 
for the radioimmunoassay* 
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2.2 The radioimmunoassay 
The inhibin was diluted to 10,000 CPM per lOOpl 
with an assay buffer containing (KIM P04/0.15M 
NaCl/0.1% sodium azide/0.5% BSA. and also lg/1 of 
Triton X-100. Triton X-100 was used in the assay to 
reduce the non-specific binding from 4% to 0.5%^^ 
The lyophilized WHO inhibin standard was 
reconstituted with Iml of assay buffer (2000 U/ml)• 
The inhibin concentration of this stock standard was 
further diluted to 20, 10, 5, 2.5, and 1.25 U/ml with 
post-menopausal women serum (prepared by pooling sera 
from females aged greater than 60 years). lOOyl of 
inhibin antiserum was added to 200pl of standards or 
serum samples. The tubes were incubated overnight at 
room temperature. lOOyl of tracer was then added to 
the assay mixtures and the tubes were incubated 
overnight at room temperature. The following day lOOiil 
of goat antirabbit immunoglobulin G serum (second 
antibody) , or 1 mL of the DPC precipitating antibody 
was 'added to the assay mixture for comparison. The 
tubes were incubated overnight at 4°C. Finally, 2ml of 
saline was added to each tube and centrifuged at 2,400 
rpm for 45 min at 4� C . The supernatant was decanted 
and the radioactivity determined in a gamma counter. 
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2.3 Optimization of assay parameters 
1.3.1 Optimization of serum content and second 
antibody titre — 
This was done to optimize the protein content and 
second antibody titre. 
lOOiaL of rabbit anti inhibin antibody (1:2000) was 
added to 100, 200, or 400uL of PMS, and incubated 
o v e r n i g h t at room temperature. lOOpL of tracer was 
then added and the tubes were incubated overnight at 
room temperature. To each tube ImL of DPC second 
antibody was added, followed by centrif ligation to 
remove the supernatant. 
’ Alternatively, lOOpL of neat, 1/10, or 1/100 of 
Serotec sheep anti rabbit antibody was added as the 
precipitating reagent, and the tubes incubated 
overnight at room temperature. ImL of NaCl was added 
to all tubes before centrif ugation at 4�C for 20 
minutes. The supernatant was aspirated and the 




2.3.2 ^  Verification of second antibodies' precipitating 
i ‘ 
activity 
This was done to check if the ‘ Serotec' and the 
‘ - D P C second antibodies were both capable of 
precipitating the rabbit primary antibody. 
50]aL of rabbit anti growth hormone antibody was 
added to 50pL of zero growth' hormone standard. The 
reaction mixture was incubated for 1 hour at room 
temperature • Then 50ul of the tracer was added to each 
tube and incubated for 1 hour at room temperature. 
To precipitate the antigen antibody complex, 
either 500]jL of the DPC precipitating reagent or 50pL 
of Serotec antibody (at neat, 1/10, 1/100卜or 1/1,000 ‘ 
dilution) was added and the tubes with the ,DPC, 
antibody were centrifuged at 4,000 RPM for 20 minutes 
at The supernatant was aspirated. The reaction 
with 'Serotec' antibody was performed overnight, 
followed by addition of 450uL saline solution and 
centrifligation at 4,000 RPM for 20 minutes at The 
tubes were counted for 1 minute. 
2. INHIBIN_EASIA47 
- P r i n c i p l e of the test 
INHIBIN-EASIA is a one step two side ELISA 
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performed in microplate- It allows quantitative 
) 
determination of human inhibin in serum, plasma, 
— follicular fluid and other biological fluids. Both 
specific antibodies used in this sandwich assay 
r e c o g n i z e distinct epitopes of the a subunit of human 
inhibin* An affinity chromatography purified anti-
inhibin goat antibody is coated on the microwells. The 
enzymatic conjugate is a mouse monoclonal antibody 
labelled with Horseradish peroxidase. 
3. Progesterone^^ 
- p r i n c i p l e of the test 
The Coat—A—Count Progesterone is a solid-phase 
radioimmunoassay, where ^^^I-labelled progesterone 
competes for a fixed time with progesterone in the 
patient for the antibody which coated on the wall of a 
polypropylene tube. The reaction is stopped by either 
aspirating or decanting the supernatant. Counting the 
tube in a gamma counter which yields a count rate that 
can be converted by way of a calibration curve to a 
measure of the progesterone present in the patient 
sample. 
4. Oest:radiol49, LH^O, and FSH^^ 
-Principle of the tests 
The three serum hormones were measured by the use 
of Abbott IMx^ assay which is a Microparticle Enzyme 
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Iimnunoassay (MEIA). The IMx hormone assays are based 
on . the Microparticle Enzyme Imnmnoassay (MEIA) 
technology. The samples were added to a well containing 
the capture antibody (directed against the S subunits 
for LH and FSH respectively) coated microparticles and 
buffer containing surfactant where they form an 
antibody—antigen complex. An. aliquot of the reaction 
mixture containing the hormone bound to the antibody 
coated microparticles was transferred to the glass 
fibre matrix. The matrix was washed to remove unbound 
materials• For oestradiol, the oestradiol-alkaline 
phosphatase conjugate was dispensed onto the matrix 
where it binds to the unoccupied antibody binding 
sites. Anti-aLH subunit specific alkaline phosphatase 
conjugate for LH, and anti-aFSH subunit specific 
alkaline phosphatase conjugate for FSH; is dispensed 
onto the matrix and binds to the antibody—antigen 
complex. The matrix is washed to remove unbound 
material. The substrate, 4-inethluinbellif eryl 
phosphate, is added to the matrix and the fluorescent 




Tn-house Tnhibin A s � Y development 
1. Iodination and Purification 
Three iodination trials were done, but only one 
I set of results is shown here to illustrate the work 
done. 
1.1 step 1: Iodination followed by Sephadex column 
purification 
Figure 3 shows the elution profile of l^Si-mhibin 
after a Sephadex G-25 column purification; note that 
fractions 5-8 contained the major peaks of 
radioactivity. On the other hand, Table I shows the 
amount of radioactivity associated with protein after 
precipitation with 3% Trichloroacetic acid. Fraction 
6 which contained the highest level of radioactivity, 
82%'of radioactivity was associated with protein. 
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CHROMATOGRAM OF THE jODINATED PROTEIN 
Sephadex gei c o l u m n pur i f icat ion 
Radioacfiviiy (CPM/10uL) (Thousands) 
2000 
1 5 0 0 - ••： 
, 1 0 0 0 - • • •" •• 
5 0 0 ……… 
J 、 一 、 
0 … 卩 力 ‘ ！ ！ 
0 5 10 15 2 0 2 5 Fraction number (1 ml/fraction) 
Elution profi le 
Figure 3 
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Table I. Radioactivities and protein specificities of 
the fractions collected from丨 the Sephadex column 
\ ‘ 
Fraction no. CPM 丨 Protein % protein 
specific CPM specificity , 
1 60 59 98 j f 
2 7 9 5 0 63 I! 
3 7 9 5 1 6 5 : 
4 1 4 3 106 7 4 I 
••"：•.••  ！ ^ 
5 7 3 8 1 8 3 2 8 2 4 4 4 ！ 
6 — — 1 7 9 0 9 6 1 1 4 7 3 4 1 1 8 2 ！ 
7 __131717 69438 53 
— L — — 49101 27432 56— — — | 
9 5 0 6 6 4 — 2 5 0 8 7 5 0 _ ！ 
1 0 6 0 8 7 4 — — — 2 4 2 9 2 4 0 
1 1 一 7 6 9 0 3 — 2 4 5 8 2 3 2 ！ 
12 _ 9 9 ^ 5 9 25479 26 | 
13 一 — — _152016 29417 19 | 
1 4 1 6 7 0 5 6 — — 34336 — 20 \ 
^ —_173094 — — 33481 20 | 
16 176234 33739 — 1? j 
17 p e l 5 9 29940 22 [ 
1 8 __ 96899 — 25640 26 
19 —7770—5 — — — 24283^ 31 i 
2 0 7 0 8 8 2 2 3 1 7 2 —33 * 
Kits - - r~ --s-sr-s-sssr- — -s- ht- - : : " “ 二 " " "“ 
Fraction number 6 was taken for further 
purification by a Red A gel column for its high 
--radioactivity and protein specific activity* 
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1.2 Step 2: Red A gel column purificatic^n 
The Sephadex column purified iodination product 
was further purified with a Red A gel column. Greater 
than 94% or greater of the radioactivity of the 
product of this purification step was found to be 
protein associated (Table 工工）• 
Table 11* The assessment of the product of the Red A 
gel column purification 
Sample Total CPM per CPM per % protein 
volume lOul lOpl specific 




' S t a r ^ g 10 179072 159490 86 
material, SM — — 
Wash 1, Wl — 136040 119378 ！ 5 — 
Wash 2； W2 10 134594 113546 £0 
Wash 3, W3— � — 46160 40876 — — J ^ 
Wash 4 1 271226 258306 94 
fraction 1, 
W4.1 -—._____— 1 
Wash 4 1 37706 37292 99 
fraction 2, 
W4.2 •.. L ..._：. ••...—: 
1 10278 10196 99 
fraction 3, 
W 4 . 3 = . ： = _ = 
— - - - - — 
_ After the Red A gel purification, the product was 
further purified by another Sephadex column. 
1.3 Step 3: Sephadex column purification 
The second Sephadex column purification showed 
that there was some improvement on the protein 
33 
associated radioactivity (Table III) • The protein 
associated radioactivity was nearly 100%. Some of 
products were found to have protein associated 
radioactivity of greater than 100% but that was 
probably due to some counting error. 
Fraction no. 3 and 4 of W4.1, fraction no. 3 of 
W4.2, and fraction no. 4 of W4.3 were pooled for 
i 
subsequent RIA use. 
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Tabje 工II. The recovery study of the second Sephadex ^ 
column jpurification step i 
Fraction no. CPM per lOpl CPM per lOyl % protein 
(From W4.1, fraction of the — specificity 
W4.2, and ,, fraction 
W4.3 (protein 
respectively) specific 
. ‘ a c t i v i t y ) 
W4.1 1 148 Not done Not done 
__2 3 662 Not done . Not done 
_ 3 ___ • 1..?.3?96 illZil IZ 丨 
4 互 —.. 4 0 5 5 1 — — 1 0 1 — ！ 
5 _ — 2 7 8 4 _ _ _ . 上 — 2 7 4 6 — 9 9 — 
6 __ 1288 Not done Not done — 
7 __ 570 — Not done_ Not done 
8 „ � 4 0 Not done Not done 
—— 9 _ 250 Not done — Not done 
10 262 — Not done Not done 
W_4_.2 1 130 Not done Not done 
2 —374 Not done Not done 
3 — 2 3 3 2 4 23632 „lpJL. 
„ 4 — JL8 8 Not done Not done 
5___ _ 184 Not done ——…Not done 
— 6 188 Not done Not done 
_7__ …. 180 Not done Not done— 
_ … ― 1 7 0 Not done Not done 
9 — 边 — Not done—• — .•—•——..Not done | 
10 188 __ Not done 
W4 . 3 _ 1 304 — — Not done — N o t done 
2___ 204 — Not done Not done 
: 3 7054 7547 107 — 
4 — 6413 984 15_ 
5 156 __一 Not done Not done 
_ 6 — 136 Not done Not done 一 
— 7 — „_ — — 160 Not done Not done — 
8 — 176 Not done Not done 
9 — 186 Not done _ _ __ Not done_ — 




2. Inhibin RIA : Binding and antibody dilT|tion curve 
experiment 
The results are shown in table IV. Note that the 
• total counts added were approximately 30,000 CPM 
instead of the recommended 10'000. 
The greatest amount of antibody—tracer binding 
yielded was less than 2% of the total count. 
Therefore, there was no significant binding of the 
tracer by the inhibin antibody at various titre and 
precipitating the antigen- antibody complex with two 
different second antibodies. Similar results were 
obtained twice. Repeating the experiment with a new 
batch of inhibin for iodination yielded similar 
results. 
Therefore, the problem might have been due to the 
first or second antibodies for the RIA. To resolve 
these two possibilities, we did further experiments to 




Table IV• Results of the binding and antibody dilution )! 
curve experiment on the inhibin RIA 
(NSB: Non specific binding B/T : Bound/Total) 
i Tube Standard Inhibin B/T(%) B/T(%) 
no value antiserum (DPC (Serotec 
. • (u/ml) titre . ..A?丄生2包)• 
— • • 1 — : Total .:• 100 
2 NSB -_ _ _ l'Q5 
""3 “ NSB __ -― 0 . 9 9 — — 0.97 
4 ____ 0 — 1/200_ — — … 1 . 2 3 — — 1.44 
— i - 二 — 0 — 1/200 — l ._31 — . — — — ^ . 3 1 j 
6 20 __ 1/200 Missing—— 0*27 — | 
7 — 1 /200 1>16 — 0 - 4 6 | 
— y Z I Z n 1/400 1.87 l.ei 1 
’ . [ 二 二 — 1/400 1.55 0.73 ：！ 
— 2 0 … 1 / 4 0 0 — Q.70 I 
— i T — : 20^ 1/400 2,16 0.88 . 
12 0 _1/800 1>31 1.17 ‘ 
13 0 1/800 1.28 0>67 丨 
1 £ 20^ _ _ _ 1 / 8 0 0 0>92 — 0.64 ： 
15 20 1/800 0.96 0-34 | 
16 — 0 1/1 ,600 — 0，66 | 
17 0 1/1,600 0 . 89 Q>64 
18 20 1/1,600 2.15 _____ —广... 
19 20 1/1.600 1.46 1 • 64 
20 厂 Pooled 1/1,600 1.50 0.50 • 
serum ... — | 




3.1 ；Verification of binding activity of the second 
I - ‘ • 
antibody 丨 , . 1 
i 
The experiment shows that the ,DPC, second | 
, : I 
antibody precipitated the antigen antibody complex of 
growth hormone tracer and the anti growth hormone 
antibody with the maximum binding of about 32% (B/T). 
As for the ‘Serotec' second antibody, the maximum 
binding was about 37% (Table V)• 
Table V. Results of the verification of the binding by 
•Serotec' and ,DPC, second antibodies of •DPC• growth 
hormone first antibody 
( N ^ : Non specific binding B/T: Bound/Total) 
Tube no. Sample__ Second antibody CPM B/T (%) 一 
— — 1 — Total — 11,392 — — 
2 __NSB — DPC (Neat) 100 — 0_：8 
3 — — NSB DPC (Neat)— 73 — 0：6 
4 — —_；_0' Std DPC (Neat) 3,687 ~ 32.4 
5 '0' Std —DPC (Neat) — 3,550 3 1 . 2 
6 NSB Serotec (1/1,000) 93 0：8 
7 —__ NSB Serotec (1/1,000) 78 0^1 — 
8 ,0’ Std Serotec _[Neat) . 色 ‘ 且 ？ . 38-7— —••• 
9 ,0, Std Serotec (Neat) 4, Oil 兰 
10 —_;_0 , Std Serotec (1/10) _ 2 , 808 24^6 
11- —__,0' Std Serotec (1/10) 2.791 24.5 — 
12 — '0' Std Serotec (1/100) 13V U 2 — 
13 , 0 • Std Serotec (1/100)— _ 143 1. 3 
14 '0' Std Serotec (1/1,000) 208 1.8 
15 ‘ 0 ‘ Std Serotec (1/1,000) “ 151 1. 3 
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This experi^ment verified the binding activity of 
the 'DPC ‘ second' antibody. As for the * Serotec ‘ second 
antibody, the neat concentration caused the highest , 
precipitation of the tracer. From this exberiment, it 
. may be concluded that the second antibodies were able 
to precipitate the primary rabbit antiserum. 
3.2 Optimization of serum content/ second antibody 
titre 
The highest B/T yielded in this experiment was 
less than 3% (Table VI) . The results showed that there 
was no significant yield of antibody-bound inhibin-
tracer either using the 'DPC' goat anti rabbit 
precipitation antibody or ,Serotec, sheep anti rabbit 
IgG at all of the titre attempted. Various volumes of 




Table VI • Results of the experiments in optimization of v 
serum content and second 控 . . . . . \...… 
B/T PMS PMS PMS 
-(%) lOOyL 200yL iOOjaL 
DPC 2.51 2,67 2.78 3.03 2.80 2.68 
Serotec 2.92 2.43 1.69 2.09 1.96 1.18 
(Neat) 
Serotec 1.36 1.55 1.05 3.63 1.92 1.43 
(1/10) 
Serotec 1.10 1.04 1.25 1.13 1.15 1.93 
( 1 / 1 0 0 ) : — ： … 一 一 - … … … … 、 “ 
Note:Total count 二 10,219 CPM 
Non-specific binding, NSB = 69 and 59 CPM 
respectively as measured using 'DPC second 
antibody in duplicate. 
‘ B/T = Bound/Total 
PMS 二 Post-menopausal women serum 
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4. Discussion and conclusion 
It would appear that the iodination procedure used 
in this study yrelded a tracer which was almost 86% 
protein specific and upon further purification, the 
specificity went up to almost 100%. However, when the 
binding of the tracer by the inhibin antibody was 
attempted, there was very little binding (less than 
10%). Further experiments supported the view that the 
i lack of binding was due mainly to the first antibody. 
It is possible that the inhibin antibody may have 
deteriorated during its storage at although it 
seems unlikely considering the robustness of antibodies 
in general. Unfortunately, further batches of the 
rabbit anti Inhibiri antibody was not available for 
verification of the hypothesis• 
In view of the time limit of this study, 
commercial inhibin kits were employed to complete this 
project. 
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Part II ， 
Hormone Resultjs of Women Undergoing in vitro 
i • � 
Fertilization , 
1. Presentation of analytical results 
Figures 4-28 show the hormone results of the two 
groups of patients in the long and short GnRH agonist 
regimes respectively, while the results of individual 
patients are tabulated in appendix 3. All the timing 
of the hormone profiles are normalized to the day of 
hCG administration (ovulation induction)• 
Please note that for each of the GnRH agonist 
regime, patients were given the gonadotropin(s) as pure 
FSH and/or hMG. In the short regime, two patients were 
on FSH plus hMG, and four patients were on hMG only. 
In the long regime, two patients were on hMG only, one 
patient was on FSH plus hMG, and five patient were on 
FSH alone. 
The choice of the gonadotropins used was based on 
the patients‘ response, e.g. as monitored by ultrasound 
imaging or serum E�r e s u l t s . Also, the patients ‘ 
response in previous ovarian stimulation attempt(s) was 




The graphs shown in figures 4-28 are the profiles 
I . 
of individual patients without any generalization 
treatment which were prepared by using a computer 
software, Harvard Graphics^^. Since the time of sample 
collection was not synchronized (it is a pity that the 
ward protocol was not followed strictly), it is 
difficult to work out a generalized curve for each 
hormone, i.e. calculate the mean level of the hormone 
on each day of sample collection. Attempts were made 
to find out a way to work out hormone profiles for 
these patient groups, e.g. a balanced incomplete block 
design, or partially balanced incomplete block design 
treatment^^. However, the patient results data were 
limited. These data treatment methods do not work if 
the experimental data obtained at each time of sample 
collection were less than 2. Because in no cases were 
there more than 2 data points for each collection time, 
working out a generalized profile was not feasible. 
2. Comparisons of hormone profiles of patients in the 
two GnRH agonist regimes 
2.1 Gonadotropins 
(a) FSH 
Although there was exogenous plus endogenous FSH 
in patients in the short GnRH agonist regime, the 
results were similar to those of the patients in the 
long regime (figures 4-8). One exception was patient 
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number 2 (figure 5) . She was given hMG for a period 
longer than the others, probably due to poor response 
of the patient, and the maximum level was deviated from 
the mean of one day before hCG administration. 
Further, whether the patient was on hMG alone or in 
combination with pure FSH did not affect the hormone 
profile pattern. 
‘ Within the group in the long GnRH agonist regime, 
since the pituitaries were down-regulated, the measured 
FSH levels must have been due entirely to exogenous FSH 
administered. In this group the gonadotropins 
administered were either as hMG, FSH, or the 
combination of. the two. The serum FSH dropped as the 
exogenous FSH administration was stopped. In these 
patients prepared for in vitro fertilization, 
gonadotropins were stopped before hCG was given. 
Therefore, the FSH peak levels were found one day 
before hCG was given (figures 6-8)• This pattern was 
found in all the patients in the long GnRH agonist 
regime irrespective of the form of gonadotropin used 
(FSH and/or hMG)• 
In general, no significant difference in FSH was 
found among the two groups of patients in the long and 
short GnRH regimes. Moreover, the form of exogenous 
gonadotropins (FSH and/or hMG) administered did not 
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(b) LH 1 
！ 
— Patients in the short GnRH agonist regime had LH 
profiles very similar to their FSH profiles, in that 
they all had one peak about one or two days before hCG 
was aciministered (figures 9-10) . One exception was. 
again, patient number 2, who had a second peak at ten 
days before hCG was given. 
• The LH levels were significantly lower in patients 
in the long GnRH agonist regime (all LH levels < 2 
lU/L) compared with those in the short regime; except 
patient 4, who had a peak LH level of 13.3 lU/L, 
— comparable with those in the short regime (figures 9 — 
13). Moreover, some of the patients in the long regime 
did not follow the same pattern as those from the short 
regime. The two patients in the short regime 
supplemented with hMG only, both had a trough level 
before their LH levels rose to a peak. Patient 8 in 
the long regime, who was given pure FSH, had LH level 
which fell from a maximum of 2 工U/L at the beginning to 
an even lower value, but in general, all patients given 
FSH alone had LH level below 3 lU/L. 
Overall there was no observed dependence of LH 
levels on the form of exogenous gonadotropins (FSH 
and/or hMG) administered. 
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In general, the profiles of both groups of 
patients were very similar (figures 14-18). There was 
an overall trend of E�increase with a maxima at day 0, 
and a minima at day 3 after hCG administration • 
Moreover, no significant difference in the level of 
was found in the two regimes. Patient 4 in the long 
regime seemed to have the post hCG E� p e a k missing, but 
it was probably due to a lack of post hCG data of the 
patient. (The only post hCG data was on day 13 after 
hCG administration.) 
On the other hand, the dependence of on the form 
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2.3 Progesterone 
In both regimes, the progesterone levels remained 
very low 5 days before HCG administration (figures 19-
23) • And all the patients’ progesterone rose to a 
plateau (the detection of the maxiinum point, peak 
level, was limited by the detection limit of the assay 
system; which has a highest detection limit of 127 
nmol/L) ten days after hCG administration. 
Similar to the case of Eg, the dependence of 
progesterone on the form of gonadotropin (FSH and/or 
hMG) administered was not observed. 
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2.4 Inhibin 
In both regimes, there was an overall trend of 
increase in inhibin levels (figures 24-28). Moreover, 
the hormone level of patients were similar in both 
groups; except patient 5 in the long protocol who had 
inhibin levels higher than all others on all the 
normalized days of sample collection. 
Again, the dependence of inhibin on the form of 
exogenous gonadotropin (FSH and/or hMG) administered on 
the inhibin levels was not observed. 
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3• Relationship between hormones ; 
! 
Limited by the number of patients in each regime 
- and also the fact that we are not able to produce 
generalized curves for each hormone for the two 
regimes, we tried to find out any relationship between 
the hormones by observing the hormone profiles of the 
patient on a case by case manner. Also, an attempt was 
made to work out correlation between the hormones, but 
limited by the amount of data available a simple linear 
regression analysis. We understand that these hormones 
may not have simple linear correlation, and we should 
use more vigorous approaches e.g. an analysis of 
variance (ANOVA) if we have more data. 
3.1 Relationship between hormone changes 
Firstly, we tried to work out the relationship 
between the hormones by comparing hormones on the same 
time scale, normalized by the time of hCG 
administration, case by case. We tried to find out 
whether the hormone profiles rose or fell in a similar 
manner, i.e. the curve gradients were of the same sign 
； o r the profiles went in an opposite direction, i.e. 
the gradients were of opposite sign. 
To illustrate how we tried to found out their 
relationship, consider figure 29, patient 2 in the 
short regime, the FSH and LH profiles rose and fell in 




‘t sign. Therefore, the patient's FSH and LH changes were 
I positively related during the pre- and post- ovulation 
phases. (This is not surprising as the patients were 
given exogenous hMG.) 'As for the relationship between 
FSH and inhibin, both hormones rose in the pre-
ovulation phase, with their profile gradients of the 
same sign (positive) • However, FSH fell after 
ovulation when inhibin continued to rise; as a result, 
the two hormone profile gradients were of different 
sign (FSH, negative versus inhibin, positive), 
： Therefore, the changes in FSH and inhibin levels were 
: positively related during the pre-ovulation phase but 
； negatively related in the post-ovulation phase. 
^ Consider figure 30, by similar reasoning, the changes 
in progesterone and inhibin were positively related in 
both pre- and post- ovulation phases. As for the 
relationship of and inhibin the changes in E^ levels 
were paralleled by inhibin in the pre- ovulation phase, 
but not in the post-ovulation phase. There was a 
turning point of change on day 5 after ovulation, so 
there was no simple relationship of changes in level 
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Let us take patient 4 in the long regime as 
another example to illustrate how the hormone level 
changes relate to one another. Consider figure 31, by 
reasoning, as the first example, the patient's FSH and 
LH changes were positively related; while the FSH and 
inhibin changes were positively related in the pre — 
ovulation phase, and negatively related in the post-
ovulation phase. Consider figure 32, progesterone and 
inhibin changes were positively related both in the 
pre- and post- ovulation phase. (Note that the post-
ovulation plateau of progesterone might be due to the 
limitation of the detection limit of the assay system.) 
^ Also from figure 32, E? and inhibin changes were 
positively related in the pre- ovulation phase, and 
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‘ Patient 6 in the short regime was an interesting 
example (figures 33-34). The patient's inhibin level 
fell in the post- ovulation phase after 了eaching a peak 
value of 13.9IU/ml on day 15 while in most other 
patients, there were no post- ovulation inhibin peaks 
observed. One can argue that we might just miss this 
inhibin peak in other patients if their inhibin levels 
. w e r e not monitored until day 15 post- ovulation to see 
this maximum point. ‘ However, patient 3 in the long 
regime showed a similar* inhibin trend at the post — 
ovulation phase (figure 35-36). Also, note that the 
inhibin turning point was found on day 4 post-
ovulation in patient 4 in the long protocol. 
Therefore, probably there were a non—uniform inhibin 
changes among different individuals; some patients, 
inhibin levels reached a peak within 15 days after 
ovulation, while others' inhibin continued to rise in 
the situation of falling FSH levels. 
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t 
The evaluation process as shown above was repeated 
to other patients for relationship of inhibin to FSH 
E2, and progesterone. The reading can refer to appendix 
3 for the individual patients‘ hormone profiles* The 
results are shown in table VII. 
Table VII. Inhibin level changes in relation to other 
hormone changes 
HOR- — — Short regime 
Pre- ovulation —— Post- ovulation 
1 ]—2 3— J _ _5_ _ _ 6 — 工 」 1 2 3 4 5_ __6_ 7— 8 
FSH + —N J J _ — — + _ _ _ _ _ _ _ _ _ _ _ 二— 二...•„__：— _N 
E, + + + + + + 丄 N _ N ^ N t— N — —__ 一_ 
— 2 — ： 
p + + + + [ + 1 + 1 J [_+ + I + I + I + . N I 
— Lc^g regime 
Pre- ovulation — — P^ ^^ t二 ovulation 
F S H +_ J - _+ + + — __+ + — __ +—二—..•二—N— - - N ： 
E + + + + 士 +— — _ _ t _ . � — N _ N +— _N_— _N __+ j 
p + + + + + + + + + + N + + ^N + 
patJgnt nuiber I 
+ 二 Positive relation in level changes 
- = N e g a t i v e relation in level changes 
N = Not application due to presence of 
turning point in one of the hormone 
P = Progesterone 
In general, inhibin was found to be negatively 
related to increasing amount of FSH in the pre-
ovulation phase in all the patients studied. However, 
in some of the patients there were inhibin peaks found 
at post- ovulation phase monitored in face of the 
falling FSH, Therefore, there was no general trend of 
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I 
I inhibin changes in relation to the FSH level after 
丄 i I ovulation. “ 
Inhibin levels showed a positive change to 
increasing and progesterone levels in the pre-
ovulation phase. The E^ profiles of a number of 
patients showed a turning point after ovulation, so 
there was no simple general relationship with inhibin 
changes. Except fbr patients with post- ovulation 
inhibin peaks, progesterone levels showed similar 
increasing trend as inhibin. 
There seemed to be no particular difference in 
hormone changes among the two groups of patients in 
various GnRH agonist regimes. 
3.2 Regression analysis 
Multiple linear regression analyses of the data 
were done for pre- ovulation phase with data from first 
sample collected up to one day before ovulation, and 
for post- ovulation phase with data starting from day 
one after ovulation to the last day. The results of 
the analysis by the use of a statistics computer 
software, ABstat^^ is shown in table VIII. 
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Table VIII�. Multiple linear regression analysis of the 
hormones measured versus inhibin 
二:•””.”-!，:-•‘•‘••一 二 ••：“;；;::-““:-“-“i:厂“-•-•“-•-•“““““•• * 
Hor- Pre- ovulation Post： 
阳 Short regime Long regime Short regime Long 色 
. corr Pr Corr Pr Corr Pr C o r r . Pr 
E ^ + 0 . 4 1 + < 1 0 - 4 + 0 . 2 3 + 0 . 0 2 
L H + 0 . 3 8 + — 0 . 6 2 : 0 . 8 5 : 0 , 5 3 
F S H + 0 . 6 7 + 0 . 3 2 + 0 * 5 1 — + — 0 . 8 2 
p + 0 . 1 3 - 0 . 2 6 + 0 . 4 2 - 0 . 7 5 
• • - n. - —""二 ：一 ： =“ “ 
Note': “~Corr Correlation, only the sign or 
correlation is given here 
Pr Probability 
P = Progesterone 
The probabilities of the correlations of the 
regression analysis were very low. For example, 
although the results show that FSH was positively 
correlated with inhibin in both regimes in pre — and 
post- ovulation, phases, the probabilities were less 
than 0.82. Therefore, we are not confident enough to 丨 
draw any conclusion from this analysis. Such an j 
outcome is not surprising, as the data may not be 
linearly correlated. Therefore, we need more patient 




IV. DISCUSSION V 
j 
A study on the effect of ovarian stimulation on 
“inhibin in women undergoing in vitro fertilization 
1. Hormone profiles 
The gonadotropin levels of these patients were not 
physiological as they were all under GnRH agonist 
administration and gonadotropin supplement. Although 
the endogenous FSH and LH level were down regulated in 
patients of the long GnRH regime, they were given 
exogenous FSH and/or LH. Therefore, the FSH and LH 
levels of patients in the long regime actually reflects ^ 
the types of gonadotropins given to them. 
Even though patients in the short protocol had 
exogenous plus endogenous gonadotropins, their serum 
FSH and LH were controlled by adjusting the amount of 
exogenous gonadotropin given. Therefore, patients in 
both regimes had very similar gonadotropin profiles. 
Although FSH levels in both groups were not 
significantly different, the LH levels of patients in 
the short GnRH agonist regime were higher than those in 
the long regime irrespective of the form of 
gonadotropin (FSH and/or LH) administered. This 
implies that the endogenous LH contributed 
significantly to the LH levels in patients in the short 
regime. 
In the two patient groups studied, the exogenous 
gonadotropins administered superseded their 
physiological control. The gonadotropin levels in 
these patients can be treated as incaependent variables 
in the sense that their levels were controlled 
artificially; although not totally, in patients in the 
short GnRH agonist regime. The amount of gonadotropin 
was given according to the patients' response. For 
‘ example, if the patients had LH level relative to FSH 
(high LH:FSH ratios) and they are high responders to 
GnRH. These patients are best managed with low-dose 
gonadotropin because they are susceptible to a pre-
matured LH surge which would lead to the yield of 
disprdportionate number of immature oocytes. These 
oocytes are of very low reproductive 
potential^^Moreover, an increase in FSH (low LH:FSH 
ratio) raises the number of oocytes collected, and the 
number of embryos and pregnancies obtained . 
Therefore the high responders who may give increased LH 
response to GnRH are given purified FSH instead of hMG 
for ovarian stimulation. 
Therefore, we were working with ovaries with 
normalized activities by artificially tuning in the 
gonadotropin levels. It is reasonable that the ovarian 
synthesis of E � w a s normalized among the patients 
studied as well. Thus, the Eg levels and profiles 
within each regime group were similar. The effect of 
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the short and j.ong GnRH agonist regimes was to up- or 
down-regulate the pituitaries. But, there was no 
effect on the between group difference in E� l e v e l and 一 
profile pattern. Progesterone secretion during the 
follicular phase is mainly contributed by the ovary. 
The results of the study also show that the within and . 
between regimes progesterone level and profiles were 
very similar. 
t 
2. Hormone correlation 
With the exception of inhibin, the hormone profile 
patterns of this study were very similar to those 
obtained by Urbankcsck et al^^ who studied patients . 
with exogenous hMG without GnRH agonist stimulation. 
They showed that serum inhibin was positively related 
to an increase in FSH both in the pre and post 
ovulation phase. However, the present study showed 
that inhibin increased with time even after ovulation 
in many of the patients studied. 
The initiation of inhibin studies had been due the 
observations of discrepancies of expected parallel 
control of serum FSH and LH levels by GnRH, FSH and LH 
levels respond to GnRH stimulation in a parallel 
fashion. But after the establishment of inhibin-FSH 
control concept, the mechanism of FSH control should no 
longer be related to GnRH levels only. In this study, 
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the FSH and LH profiles were J^ound to be parallel to 
！ • 
one another roughly. Such parallel changes in the pre— 
ovulation phase were contributed by exogenous 
gonadotropin. As the lowering of FSH levels in the 
post- ovulation phase were also found in LH 
simultaneously. The decrease in FSH levels were not 
contributed by the selective inhibition of FSH release 
by the action of inhibin. Such a lowering of 
gonadotropins could have been caused by a lowering of 丨 
GnRH alone or the combination of lowering of GnRH and 
increasing inhibin levels• The post- ovulation phase 
results of patient 3 in the long GnRH agonist regime 
shows this point. Her post- ovulation inhibin levels 
fell as her FSH levels decreased. Therefore, her post-
ovulation FSH lowering could not have been due to the 
increase of inhibin, as one would have expected. 
The pre- ovulation elevation of inhibin can be 
explained by the release of inhibin in response to the 
elevated FSH either from endogenous and /or exogenous 
sources. The post- ovulation lowering of FSH after 
stopping exogenous gonadotropin was less well defined 
because the patients' inhibin responses were not 
uniform among the two groups of patients. Therefore, 
the role of inhibin in contributing to the lowering of 
post- ovulation phase FSH levels was unresolved. 
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On the other hand, there was no effect of up- or 
down-regulated pituitaries on inhibin profile patterns 
as shown by the trend— of increase in inhibin levels 
before hCG administration in patients of both GnRH 
agonist regimes. For the post hCG adniinistration 
period, the inhibin profiles were not uniform in the 
two groups of patients in response to the decreasing 
FSH levels. This phenomenon needs more investigation, 
i 
Much more work has to be done to fully appreciate 
the role of inhibin in FSH control at the post 
ovulation phase. At least one has to recruit more 
patients to increase the population size. Hopefully, 
whether the exceptional case of the patient 3 of the 
long regimes was a real exception can be resolved. 
Moreover, the importance of the synchronization of 
serum sample collection by the ward colleagues has to 
be stressed, so that the significance of the data 
collected can be maximized. 
93 
« 
： V. CONCLUSION 
( 
： This project studied inhibin, levels in women with 
ovarian stimulation to prepare for in vitro 
fertilization. The endogenous control over FSH level 
was overridden by exogenous gonadotropin(s) in the pre — 
ovulation phase to induce super—ovulations in this 
patients. 
This study showed that the inhibin level gave a 
positive response to the rise in FSH level no matter 
whether the patients were up- or -down regulated in the 
pre- ovulation phase. However, the patients' inhibin 
profiles were not uniform in the post- ovulation phase 
in both groups• Therefore relationship of inhibin to 
the falling gonadotropin in the post- ovation phase was 
not defined. 
The results of this study also showed that the 
form (FSH and/or hMG) of exogenous gonadotropin used 
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: " PROTOCOL FOR STUDY ON IVF M H INHIBIN 
\ - ‘ 
j 
Management of IVF cycles will be conducted according to the usual 
protocols. " 
There will be 15 patients on the Long protocol and 15 on the 
Short protocol for the Inhibin study. 
(1) Long protocol patients 
Blood on Day 1 HMG 
and then every third day until day of HCG 
Blood on Day of HCG Day 4 after HCG Day 9 after HCG 
Label path form HMG Day 1 or Day of HCG or Day 4 after HCG etc. 
� - - -. On these days onlv, also label all path forms "Inhibin Study, 
Long protocol". On all of these days, send routine IVF bloods, 
as well as an extra 10 ml clotted blood for "Inhibin, 
^ Androstenedione, Testosterone". On the other days when these 
patients have blood taken, do not write "Inhibin study" on the 
path forms. 
(2) Short protocol patients — . 
Take blood on day of commencement of HMG ( HMG Day 1) which 
will be Day 3 of the cycle. Then proceed witlj blood taking on 
the same days as long protocol patients. All path forms on these 
days onlv should be labelled IVF Short protocol. 
Routine IVF bloods and all FSH, LH and Ej and Prog requests 
go to normal lab. All bloods for "Inhibin, Aiidrostenedione, 





A P P E N D I X 2 > 
PROTOCOL FOR THE MANAGEMENT OF IVF CYCLES 
(Revised 11/1/93) 
(1) Long (Downregulation) Protocol 
All patients should use Buserelin nasal spray (2 puffs three 
times per day) from Day 21 of the cycle preceding the IVF cycle. 
They should come to the Fertility Clinic after using the spray 
for 2 or 3 weeks during which time they will usually have had a 
period. At that visit blood should be taken for E2, 
Progesterone, FSH and LH and an ultrasound examination will be 
performed. If: there are no follicles >10 麵 on the ovaries then 
they should' begin HMG 3 ampoules daily, and after 3 days, reduce 
to 2 ampoules daily. On the 5th day of HMG, blood should be 
taken for E2 and LH. Thereafter blood will be taken daily, and 
ultrasound examinations will be performed once the E2 level is > 
1000 • The spray is continued throughout the cycle until HCG 
10,000 lU is given, which will be when there is at least one 18im 
follicle and a minimum of 3 follicles > 14iam. • 
(2) Short (Flare) Protocol ^ 
An ultrasound examination is performed on Day 2 or 3 of the 
treatment cycle, and assuming that no ovarian activity is 
present, all patients should commence both the Buserelin nasal 
spray and the HMG injections in the same way as t^ iat described 
for the Long protocol. Baseline blood tests are performed on the 
same day- Thereafter, the management is the same as that for the 
Long protocol. 
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, (3) Poor Responders 
Those patients who have previously had a poor response to 
ovarian hyperstimulation for IVF will receive either 
(a) HMG 3 amps and FSH 3 amps for 3 days followed by HMG 6 
amps daily form the 4th day onwards on either the long 
or short protocol. 
OR 
(b) HMG 4 amps daily on either the long or the short 
protocol 
(4) Luteal Phase Support 
Following oocyte retrieval there will be two regimes for 
luteal phase support. The standard regime will be HCG 1500 
units every 3rd day from the day of oocyte retrieval for a total 
of 4 doses. A second regime will be used in those cases where it 
� 
is thought that a risk of ovarian hyperstimulation syndrome may 
be present, but that the risk is not so great that treatment 
cannot proceed. For these cases. Progesterone 50 mg daily will 
be given for 2 days beginning on the day of oocyte retrieval 
followed by 25 mg I/M each day for 8 days. 
Patients should come for pregnancy testing on a Monday 
approximately two weeks after embryo transfer if a period has not 
come before that day. 
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• • APPENDIX 3 ‘ 
I: • 
i INHIBIN STUDY 
Patient number ： 1 (short protocol) „ 
Age : 34 
Gonadotropin used : FSH (9 Ampoules), hMG (33 Ampoules) 
Days Eo LH Progest- FSH Inhibin 
r^ ocit HCG erone 
(pm^l/L) (lU/L) (nmol/L) (lU/D—...(工 U/mL) 
2.8 — 2 . 8 8 9.1 _0 • 5 
— . . . • • • : 竺 — 1 5 6 0 1 0 , 6 — — 1 . 1 8 
— 3780 — 8.4 — 2 . 7 2 — 19.1 — — 2 . 8 — _ 
“—•••—4— 1354 _0,5__ 95.1 3.2 — 
1 0 " " " ^ 4 2 < 0 : ^ — . _ > 1 2 7 一 一 丄 一 — 
TNHIBIN STUDY 
Patient number ： 2 (short protocol) 
Age ： 30 Gonadotropin used : hMG (81 Ampoules) 
— - ， — 一 ：二：二二 二：二二二二 
^ LH Progest- FSH Inhibin 
post HCG ( l U / L ) — ( n m o ^ L ) _aU/L)—•••(亚EkL•• 
—•::;:•:‘.• """"121 3.5 _____1.22—_ Q � — -
lie — 1.26 ——• 15.1 — — 
— ^ — 1 0 . 2 — 0 , 5 7 1 9 . 7 :..._‘•.0.2 
—：：工； — i : 置 — — ^ ^ — 込 9� .一- -
: •� : • • . — T I 5 3.5 — — 0 . 7 1 — —17 .q_ 丄 丄 ― • 
j - 6 — 6 1 3 — -
- . I T — — • 7 ^ 7 8 5.1 一 ___9�i—„—.11：..?—�—...i-:?.— 
——_3 1936 — 2_.7 
• : : [ . . • — ~ 5 3 6 2 _5., 2 5 1 . 8 6 _ _ _ — 1 ! : 立 
1 6403 — 2_._9 —— 
_ ^ 4 8 <0.5 — 
— — [ " " ^ 6 5 <0.5 60.8 ^ 
— ； 5 — 丁 2 5 3 6 - — 0 • 5 e i T " <1. 0 
, I I II . “ 
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INHIBIN STUDY 
Patient number : 3 (short protocol) 
Age : 33 
Gonadotropin used : FSH (9 Ampoules), hMG (57 Ampoules) 
- “ „ - - - : 
Days E2 LH Progest- FSH Inhibin 
post HCG erone 
(pmol/L) [lU/L) [nmol/L) (lU/L) 
" “ _ i i 0 4.7 2.32 — 1 2 . 6 0.3 
一 7 - 」 4 0 1 2 . 2 3 . 6 7 ！ 1 _ . ! . 一 
‘ 一 4 10 2 4 _ 7.52 — 1 . 6 0 1 9 . 0 — 1.3 
— 2305 1.50 24.5 3.3^ 
r — 0 3 4 3 1 1 . 7 0 2 3 . 3 
1 1 一 — 3 4 9 8 — 1.：2 ... — — — 
j 4 1259 — 0.5 42.9 ^ izl 
I ” R384 <0.5 65.6 1-0 7.1 
L _ D C O i ^ I 一 丄 ; i ^ ， _ : i = ~ : “ „ “ _ ~ a ; g « i ; a i : ; a : ; ; ; ; n : = a = s = s ! s ; a a « ; ; : n s g = i ; s y - > a s s « K ! g a 5 g ! 3 ! r « 
TNHIBIN STUDY 
Patient number ： 4 (short protocol) 
Age : 38 
Gonadotropin used : hMG (24 Ampoules) 
^ 一~ LH �Progest- FSH Inhibin 
post HCG 几) (lU/L)ZZl/L)—„.JIU/L1„——1.1^/5^1......... 
—••:6... “ —““161 3.8 1 . 6 9 — • . — i l ：卫••..— 
21.2 — — 1.72 14 ？-ll—— 
： ― 0 ^ 9 8 9.4 — 2 . 7 „ „ — M LI..•—• 
— 1 6239 — — 2 . 2 
] . ： ― ， 今 < 0 . 5 — _ _ _ _ _ _ ^：全 —— 
� • • • “ ― T e i V <0.5 >127 <1 
么丄一^  ^ 3 上' — 1 * 
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INHIBIN STUDY 
Patient number ： 5 (short protocol) 
Age : 36 
Gonadotropin used : hMG-(24 Ampoules) 
Days E2 LH Progest- FSH Inhibin 
post HCG erone 
(pmol/L) (IU / L) ilU/L) (工 U/mL) 
一 5 <90 10.7 1.63 5 —1.9 
-2 2426 10.5 4.70 20 6.5 
1 5927 10.7 2.24 _ 19 12.1— 
2一 丨 6 6 1 3 7： . 3 .„..., 
I ： ~ — 3 ^ 2 < 0 . 5 — 1 1 7 — 5 1 2 . S _ 
— 1 2 8173 <0.5 _ >127 < 1 � � 33/0 
TNHIBIN STUDY 
Patient number ： 6 (short protocol) 
Age : 28 
Gonadotropin used : hMG (21 Ampoules) 
•二 
Days E2 LH Progest- FSH Inhibin 
r^/^cii" wrr; erone 
(pmol/L) (lU/L) —(pmol/L) — ( l U / U 
‘ " - 6 132 3.2 ^  1 � 0 — 7.7 � : _ ? . — . 
: •� 2169 8.5 _ __1.._49 _ _ 10.8 4-4 —— 
- 1 3 6 3 0 7 . 7 — -
0 一 — ^ 9 2 9.6 
� ― — • — ： 6 6 � 全 8.9 — 2 . 0 8 12.1 —…――！ !•—Z 
2 5773 1.__7 — :• 
•[• ： �_ <0.5 — 116 — 2 : ? . —一 — _ H — . . . 
„„ 15 >11010 <0.5 >127 <1 „ . „ — 
一 _22_ >11010 — <0.5 … >127 11...— — • 
— f — >11010 0 . 8 >127 i L . . . — ^ l E ^ L ^ 
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INHIBIN STUDY 
Patient number ： 1 (long protocol) 
Age : 32 
Gonadotropin used : FSH (15 Ampoules). 
•；;i:^SAr»iir«iiii“““""“"M*, ••••••••••••••••  ._• "” 
Days Eg LH Progest- FSH Inhibin 
• post HCG erone 
(pmol/L) [lU/L) 1 (nmol/L) (lU/L) ilH/mL) 
- 6 1 9 5 1 . 0 1 . 2 3 6 . 0 0 . 4 
- 3 7 9 6 1 . 3 2 . 1 6 1 5 . 9 — 3 . 3 — 
0 3 7 0 3 __ _ 2 . 8 1 ^ 9 7 1 4 . 0 — 7 . 1 
4 1 5 6 0 < 0 . 5 4 7 . 2 — — — 1 . 5 
— 9 • 5 1 0 5 < 0 . 5 — > 1 2 7 “ < 1 . 0 1 1 . 7 
‘ INHIBIN STUDY 
Patient number : 2 (long protocol) 
Age • 37 
Gonadotropin used ： hMG (38 Ampoules) 
, 
f Days T Eg LH Progest- FSH Inhibin 
H m erone 
—P — (pmol/L) (lU/L) —(nmol/L) d U / D — — i L y / J S y — . 
1 - 6 , 1 . 3 1 ： 3 — — — 9 二 ? _ — — 
" " " " - 1 1 < 0 . 5 _ _ _ _ 0 . 4 — 1 0 ： 8 :..•_••.」. 
‘ “ : • • 「 士 ; 7 _ _ 0 ._6 0._5 12,9 „—.2：„5 
- 5 _ 4 3 7 1 . 5 _ 0 . 9 _ 1 6 . 4 — — ！ ： ! 
-1 198 9 1.5 1>0 J A : ! . — — ― h A — — 
— 4 1 1 9 6 < 0 • 5 2 5 . 9 —•••2_. 4 — — 4 . 2 
： ― 3 7 2 1 _ _ < 0 . 5 ^ 1 2 7 — _ — 丄 丄 」 — . 




INHIBIN STUDY t 
Patient number ： 3 (long protocol) ！ 
Age : 30 
Gonadotropin used : FSH (43 Ampoules) - - -
Days E2 LH Progest- FSH Inhibin 
iDOst HCG erone 
(pmol/L) (1£乙1^ ) inmol/L) [lU/L) ...... 
- 8 < 9 0 1 . 1 1 . 9 0 5 . 0 0 . 8 ‘ 
- 5 2 2 4 0 . 9 1 . 3 4 2 5 , 3 卫 」 
•••..••.r:2 4 7 3 1 . 0 _ • 2 9 _ 1 7 . 8 — 2 . 4 
1 " _ _ 1 0 5 7 ^ … — — 5 U 0 — _ — • 2 . 9 2 — — 2 2 . 0 5.2 
I—•.... 2826 2.7 _ _4_.7 5 23.1 — � � _ 
— . “ 6 5 ^ 6 3 . 2 . 
I" 8 7 7 " " — 2 ^ 3 _ <0.5 >127 16.0 — — 9 ： 5 
I t . ] ; V - n < 0 . 5 > 1 2 7 ] ——___0>9 丄 ! _ 
TNHIBIN STUDY 
Patient number ： 4 (long protocol) 
Gonadotropin used •: FSH (9 Ampoules), hMG (39 Ampoules) 
— — L H Progest- FSH Inhibin 
post HCG (pmoi几 )iiHf^i 二 / U ( l U / U — ( l U / n ^ L . . . . . . 
— " 3 1 6 1,0 2,66 � : ! — L:i 
— : [ — “ 2.5 . _ � : 1 5 … _ _�?.:?. ±'2 
” ―：： 1 7 5 ^ 4 13.3 _ __2.85 31,0„„..........i:! 
"0 7.3 」 . 4 9 32 . 9 
I ' 1 6 . 2 4 . 8 5 ........— 8 . 4 — 
I —4 —…—：： 28.7 ——_ 
{‘ .6 一— > 1 2 7 3 . 1 _ 
I — — 1 3 — 厂 0 • 6 ^ > 1 2 7 < 1 —— 
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INHIBIN STUDY 
Patient number ： 5 (long protocol) 丨 
Age : 38 
Gonadotropin used : hMG (17 Ampoules) 
, . • „ • - - " — •••••••••— 
Days E2 LH Progest- FSH Inhibin 
DOSt HCG erone 
(pmol/L) UU/L) [pmol/L) ilU/L) ilU/mL)— 
- 9 1 2 8 1 . 2 1 . 0 3 . 1 丄 ： 卫 — 
-5 1108 0.8 1.14 15.6 4.2 — 
“ - 2 6375 2.84 _ 18.1 13.9 — 
— 4 5711 <0.5 _ — > 1 2 7 2.9 14.6 
— . . . • • „ . 「 . 丁 ； 讀 0 � ！ 丄 " — � H L = L i L d J = 急 L 一 
TNHIBIN STUDY 
Patient number ： 6 (long protocol) 
Age • 34 
Gonadotropin used : FSH (18 Ampoules) 
LH Progest- FSH Inhibin 
post HCG (pmol/U (lU/L) _ ， =� / L ) (lU/L) — — 
— - 6 — —<90 一 _ 1.39 � � „ 
: � 1277 1.1 0.85 _ 14.1 
— 0 — 6371 1.7 _ 1,81 .12-1 ！—• 
4 3 4 1 3 < 0 . 5 9 9 . 3 丄 丄 — 」 」 . 
11 >11010 < 0 ^ >127 0.5 11 • 5 
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• INHIBIN STUDY 
V ‘ 
Patient number ： 7 (long protocol) 
Age : 36 
Gonadotropin used : FSH (18 Ampoules) -
二 I 
Days Eo LH Progest- FSH Inhibin 
noqt HCG erone 
P (pmol/L) (lU/L) (nmol/L) (lU/L) (lU/mL) 
:5 484 1.3 0.9 5.8 0,7 
5714 1.59 16.0 7-8 
1 > 13J310 」 : 全 — 2.5 1 5 . 2 — 14.5 
— — < „ 0 , 5 — _ � 5 5 . 4 _ 5 . 0 — — 3 . _ 5 
� . —9 >11010 <0.5 >127 1.2 L 22.5 — 
TNHIBIN STUDY 
Patient number ： 8 (long protocol) 
GoLdotropin used : FSH (21 Ampoules) 
„ “.-—:-.:“- 二 — • - . • … • 二“ ““ n 
- LH Progest- FSH Inhibin j 
卯 S t HCG (pnK>l/L)•• — ( l U / L ) — Z Z l / L ) ....••J!^[�t2—」.雙^1—| 
: 3 0 5 2,0 2.J0 4.6 _ 0 • 6 — j 
：空 ：―：965 1 . 2 — _ —1.47 —. h A { 
: 1354- 0 . 5 _ — — 1.32—…―._15.8 丄 ! j 
7—— — _1262 _ _ _< 0_._5 96 . 8 ？:! .:.._..」丄^^ ^^  
— . . . • — . . . . . . : 「 : - — < 0 , 5 > 1 2 7 ^ 二 」 
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H o r m o n e levels 
1 “ : A 
^ J . IS c^-g I 1� 十 ‘ 
I s O - 2 0 - 1 0 0 10 20 30 
Day post HCG 
——INHIBIN ( lU /m l ) FSH ( lU / l ) LH ( lU/ l ) 
P (x10nmol / l ) E2 (x1000 pmol / l ) 
Gonadotropin administered: FSH + hMG 
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T 一 ‘ — ^ 一 ~ • 
. PATIENT 2 
！ SHORT PROTOCOL 
丨 HORMONE PROFILES 
Hormone levels 
25 ——-——^ — — ^ ^ 
I ；必:\::::: 
丨 ： 八 艇 
I : n 卜 ‘ 一 少 J 
- 3 0 - 2 0 - 1 0 0 10 20 30 
Day post HCG 
— I N H I B I N ( lU /m l ) FSH ( lU / l ) LH ( lU/ l ) 
- s - P (x10nmol / l ) E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH + hMG 
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I • 
= PATIENT 3 
I SHORT PROTOCOL 
丨 HORMONE PROf iLES 
I I ‘ 
H o r m o n e levels 
3 0 “ ~ 
：丨二 ^ ^ ^ 
n 1 fff^-^ n 利’1 j 水 ‘ 
I s O - 2 0 - 1 0 0 10 20 30 
Day post HCG 
——INHIBIN ( lU /m l ) FSH ( lU / l ) LH ( lU/ l ) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 





I _ PATIENT 4 
I] SHORT PROTOCOL 
HORMONE PROFILES 
-. ‘ 
‘ H o r m o n e levels 
2 5 — — ^ 一 ^ 
： — A : : [ : : ‘ 
. . . 一 一 ^ ^ ^ ^ ^ I w 
0 1 I _ “ _ ‘ ‘ 
I s O — 一 2 0 - 1 0 0 10 2 0 3 0 
Day post HCG 
——INHIBIN ( lU /ml ) FSH ( lU / l ) LH ( lU/ l ) 
- e - P (x10nmol / l ) E2 (x1 OOOpmol/l) 
� 
Gonadotropin administered: hMG 
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HORMONE PROFILES ’ 
H o r m o n e leve ls 
35 — ^ — ^ " " " " ^ 
1 30 r j.—.”..: 
I 1 
25 - I 
: t : 口 ^ 
丨 阶 h ^ 。 
一 一 
I 3 0 - 20 - 1 0 0 10 20 3 0 
Day post HCG 
— I N H I B I N ( lU /m! ) FSH ( lU / l ) LH ( lU/ l ) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 









H o r m o n e levels 16 — ^ ^ — 
1 4 � 7 \ "... / - a \ •口 
：：丨:：：：夢产-
：丨：：：愈/ ：：：： 
2 � tf.......K.…….�^............. 
- 3 0 - 2 0 - 1 0 0 10 2 0 3 0 
Day post HCG 
INHIBIN ( lU /ml ) FSH ( lU / i ) LH ( lU/ l ) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH + hMG 
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！ HORMONE PROFILES 
H o r m o n e levels 
18 — ^ ^ I • 
丨 isL K.............: 
_滅:::::::::：：:=::： 
0 I I _ _ 1 — — ^ J 
I 3 0 - 2 0 - 1 0 0 10 20 30 
一 Day post HCG 
——INHIBIN ( lU /ml ) FSH ( lU / l ) LH ( lU/ l ) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH 
—— ‘ “ 
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Hormone levels 20 p — ^ ： — " " " " 
i . 
丨::L二^ — I 一 
丨 \ I 
5 1 I-
- 3 0 - 2 0 - 1 0 0 10 2 0 3 0 
Day post HCG 
— I N H I B I N ( lU /m l ) FSH ( lU/ ! ) LH ( lU/ l ) 
] P ( x lOnmol /D E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH + hMG 





H o r m o n e leve ls 
30 ^ — — 1 
I • . • 
15 L ( \......I.......: 
J 丨 其 . 
r � •/> vV; 
‘ / ^ ^ \ 
Q. • • 
- 3 0 - 2 0 - 1 0 0 10 2 0 3 0 
Day post HCG 
——INHIBIN ( lU/m! ) FSM ( lU / l ) ( lU/ l ) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 
G o n a d o t r o p i n administered: FSH + hMG 




1 LONG PROTOCOL 
^ HORMONE PROFILES 
, I ！ -�-
H o r m o n e levels 
4 0 — 一 — — — — ^ 
I • I 
Q I I rT 门 nffP^  1~~1 ：——• ； 
- 3 0 - 2 0 - 1 0 0 10 2 0 3 0 
Day post HCG 
——INHIBIN ( lU /m l ) FSH ( lU / l ) LH ( lU/ l ) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 









H o r m o n e levels 
^ 7 0 — — • ^ — " " “ 一 ~ ~ 
‘ . . . - ： • . . . . 
1 6 0 � ………..."一."•../……“..".…：………•••…..…………j 
i � / — . — 
I 5 � 卜 . 
丨 4 0 - 7 
I 4 — . — . ： I . ： — 
2 0 -
1 0 - f ..........:..:..................... 
q I I • ^ 卜 1 1 
I 3 0 - 2 0 - 1 0 0 10 20 30 
Day post HCG 
— I N H I B I N ( lU /ml ) ^ FSH ( lU / l ) LH ( lU/!) 
P (x10nmol / l ) E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH + hMG 
. 1 2 0 






H o r m o n e levels 
1 6 p — 一 ~ — — — ^ 
1 4 :―…丨丨‘ V 
1 2 卜 -I.......i. ............... 
r 1丨/ 
:「—： .射 3 t , 
- 30 - 2 0 - 1 0 0 10 20 3 0 
Day post HCG 
——INHIBIN (lU/ml) + FSH (lU/!) LH (lU/l) 
P (x10nmol/l) £2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH 
1 2 1 � 
1 
» ^ .； 
t ‘ 
！ 




H o r m o n e levels 
2 5； — — — — ^ — ^ . 
, � � . . I 
20 L•…………… -………/ •…… 
. r 續：::::: 
Q I I t' I 
- 3 0 - 2 0 - 1 0 0 10 2 0 3 0 
- Day post HCG 
——INH旧IN ( lU /ml ) FSH ( lU / l ) LH ( lU/ l ) 
P (x lOnmol / l ) E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH 





H o r m o n e levels 
1S “ 
：[二^^ 
- … ： … \ - y f . : = : : : : nLIA^ 
Q I I _ ^ Ll 1 
一 30 - 2 0 - 1 0 0 10 20 30 
Day post HCG 
——INHIBIN ( lU /ml ) + FSH ( lU/ l ) LH ( lU/ l ) 
P (x lOnmol / ! ) E2 (x1 OOOpmol/l) 







H o r m o n e levels � 
I. 
二 : = : ： 十 悉 / = ： = 
T 
- 3 0 - 20 - 1 0 0 10 2 0 30 
Day post HCG 
——INHIBIN ( lU /ml ) FSH ( lU/ l ) LH ( lU/ l ) 
- a - P (x10nmol / l ) E2 (x1 OOOpmol/l) 
Gonadotropin administered: FSH 
I 
’ 1 2 3 
mrn^ 
f x T ^ T ^ r r ^
 1 1
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 i / ， v i l ; ^
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